Making Data Simple

Al and Wendy Cornell discuss computational biology, IBM’s 5 and 5, and how technology effects health and drugs

May 05, 2021 IBM Big Data & Analytics Hub Season 5 Episode 18
Making Data Simple
Al and Wendy Cornell discuss computational biology, IBM’s 5 and 5, and how technology effects health and drugs
Show Notes

Want to be featured as a guest on Making Data Simple? Reach out to us at [[email protected]] and tell us why you should be next.

Abstract

Hosted by Al Martin, VP, IBM Expert Services Delivery, Making Data Simple provides the latest thinking on big data, A.I., and the implications for the enterprise from a range of experts.


This week on Making Data Simple, we have Wendy Cornell. Wendy joined IBM as an IBM Researcher, after spending 20 years as a researcher and leader in the pharmaceutical industry. Currently Wendy is an IBM Research Strategy Lead for Drug Discovery, and Research Life Science Liaison to Watson Health and is credentialed as an IBM Q Ambassador for quantum computing.

Show Notes
5:16 – What goes into computational biology?

8:03 – What was the attraction to IBM?

9:57 – What do you do on a daily basis?

12:58 – IBM’s 5 and 5

17:10 – Are we doing work around side effects of different drugs?

25:47 – Can technology bring down the approval time?

31:30 – What are the positives that will come out of the past 14 months?

36:58 – STEM

38:25 – What excites you the most about the future?

 IBM’s 5 and 5

Connect with the Team
Producer Kate Brown - LinkedIn.
Producer Steve Templeton - LinkedIn.
Host Al Martin - LinkedIn and Twitter